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Abstract
Background: Prevalence of both cervical cancer and Human Immunodeficiency Virus (HIV) infection are very high
in India. Natural history of Human Papilloma Virus (HPV) infection is known to be altered in HIV positive women
and there is an increased possibility of persistence of HPV infections in this population. Therefore, this study was
conducted to understand the epidemiology and circulating genotypes of oncogenic HPV among HIV positive and
negative female population in West Bengal, India.
Methods: In this hospital-based cross-sectional study, 93 known HIV positive females attending a pre-ART
registration clinic and 1106 HIV negative females attending a Reproductive and Child Health Care Clinic were
subjected to study. Cervical cell samples collected from the study population were tested for the presence of HPV
16, 18 using specific primers. Roche PCR assay was used to detect other specific HPV genotypes in the cervical
cells specimens of HIV positive cases only.
Results: Prevalence of HPV 16, 18 among HIV positive females (32.2%; n = 30) was higher than HIV negative
females (9.1%; n = 101). About 53% (23/43) of cases with oncogenic HPV were infected with genotypes other than
16, 18 either as single/multiple infections. HPV 18 and HPV 16 were the predominant genotypes among HIV
positive and HIV negative subjects respectively. Oncogenic HPV was not found to be associated with age and
duration of sexual exposure. But the presence of HIV was found to a statistically significant predictor oncogenic
HPV.
Conclusion: The currently available HPV vaccines offer protection only against HPV 16 and 18 and some cross-
protection to few associated genotypes. These vaccines are therefore less likely to offer protection against cervical
cancer in HIV positive women a high percentage of who were infected with non-16 and non-18 oncogenic HPV
genotypes. Additionally, there is a lack of sufficient evidence of immunogenicity in HIV infected individuals.
Therefore, prevention of cervical cancer in HIV positive women must be focused towards early detection of
oncogenic HPV & cervical cytological abnormality followed by an appropriate treatment.
Background
Cervical cancer is the most common malignancy among
Indian women [1]. India contributes about one fifth of
the world cervical cancer burden alone [2]. Various stu-
dies have established that oncogenic Human Papilloma
Virus (HPV) is associated with almost all cases of cervi-
cal cancer [3]. Simultaneously, outside Africa, India has
the highest number of people living with Human Immu-
nodeficiency Virus (HIV) [4] that is known to increase
the chance of acquiring and persistence of oncogenic
HPV in them [5,6]. In immune-competent female sub-
jects, an HPV infection starts appearing in genital tract
following first sexual exposure and is understood to be
cleared off with increase of age and mostly by the age of
30 year as revealed by some studies. [7,8] But, the nat-
ural history of HPV infection is known to be altered in
persons infected with the HIV and there is an increased
possibility of persistence of HPV infections in this popu-
lation [5,6]. Persistent oncogenic HPV infection
increases their risk of having cervical precancerous and
cancerous lesions [5,6]. Thus HIV positive females have
an increased chance of developing cervical carcinoma
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Little data is available to understand the existence and
magnitude of problem of oncogenic HPV in HIV
infected female population in Southeast Asian countries,
where India alone contributes the largest number of
HIV infected individuals. This data is necessary to
understand the epidemiology of oncogenic HPV among
female population with and without HIV and its addi-
tional infectivity caused by HIV infection if any. This is
also required to understand the prevalent strains of var-
ious oncogenic HPV that are prevalent in India both
among HIV infected and uninfected individuals. This
might justify the use of a currently available HPV vacci-
nation as a step towards primary prevention of cervical
cancer in India. Hence, this study was conducted in
female population (with and without HIV infection) of
West Bengal, eastern India to understand the epidemiol-
ogy of oncogenic HPV.
Methods
It was a hospital-based cross-sectional study. The study
aimed to compare the prevalence of HPV-16 and 18
among HIV positive and HIV negative subjects with
associated socio-demographic variables. The former was
selected from the patients attending the pre-ART regis-
tration clinic of School of Tropical Medicine Hospital
(only state hospital offering ART to eligible HIV
infected people in southern part of the state), Kolkata.
A total of 93 ART naïve, known HIV positive females
participated voluntarily in this study. Written informed
consent was obtained from all of them. Interview with a
pre-tested questionnaire was used to collect their infor-
mation on socio-demography and relevant sexual beha-
vior. Interview was followed by collection of cervical
cells from external os and adjoining ecto-cervical area
with the help of a cervical cyto-brush and disposable
vaginal speculum to avoid transmission of STIs among
them.
A total of 1106 HIV negative females attending a
Reproductive and Child Health (RCH) Care Clinic in a
Southern part of West Bengal area were taken as con-
trols. The controls had similar socio-economic status as
that of cases as evidenced by their income, occupation &
education. Informed consent was taken from all of them.
Brief interview was followed by collection of cervical
cells (as described in collection of specimen from cases).
The major reason for their attending the clinic was for
routine reproductive health care counseling or for getting
treatment for some common gynecological ailments.
Pregnancy was excluded from both cases and control
subjects. Collected cervical specimens were dipped into
cold phosphate-buffered saline (PBS) and transported to
the laboratories of the Department of Human Genetics,
Indian Statistical Institute (ISI) and National Institute of
C h o l e r a&E n t e r i cD i s e a s e s( NICED), Kolkata, for HPV
D N At e s t i n g .A tI S I ,H P V1 6 ,1 8s p e c i f i cp r i m e r sw e r e
used to detect these 2 genotypes (most common among
Indian females [9]) in cervical samples from both cases
and controls. At NICED laboratory, Linear Array HPV
Genotyping Test (Roche) was used to detect other speci-
fic HPV genotypes in the cervical cells specimens of
cases only. Because of cost constraints, Roche PCR test
was done only among samples collected from HIV posi-
tive cases. HPV target DNA for PCR amplification was
prepared using Amplitude Liquid Media Extraction Kit.
Amplification of target DNA by PCR using HPV primers
was followed by hybridization of the amplified products.
The assay amplifies HPV genotypes 6, 11, 16, 18, 26, 31,
33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 66,
68, 73, 82, 83, and 84. The HPV genotypes considered
high risk included 16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
55, 56, 58, 59, 68, 73 and 82. [10,11].
Statistical analyses were performed using SAS (Version
9.1 for Windows; SAS Institute Inc., NC, USA) software.
Chi-Square Test for Homogeneity and two sample T
test were performed to compare demographic variables
of the independently chosen study samples. The associa-
tions of potential risk factors with HIV/HPV infection
were estimated by means of odds ratios (OR) and 95%
confidence intervals (95% CI). All reported p-values are
two-sided. The significance level for the predictors to
stay in the model was 0.05.
Ethical clearance was obtained from the ethical com-
mittee of the National Institute of Cholera & Enteric
Diseases (NICED) before initiation of the study.
Results
A total of 93 HIV positive women and 1106 HIV nega-
tive women participated in this study. Cases and con-
trols did not differ significantly with respect to mean
age, religion and parity (Table 1). However, differences
in education, mean age of marriage and duration of sex-
ual life between cases and controls were statistically sig-
nificant (P-value < .001).
Among HIV positive study population, prevalence of
HPV was found to be 56% (n = 52), prevalence of onco-
genic HPV was 46.2% (n = 43) and prevalence of HPV
16 and/or 18 was 32.2% (n = 30). Among HIV negative
study population prevalence of HPV 16 and/or 18 was
9.1% (n = 101) [OR = 4.7; CI: 2.8 - 7.9]. Thus, HIV posi-
tive females were almost 5 times more at risk of acquir-
ing oncogenic HPV co-infection than HIV negative
females.
Figure 1 shows age-wise distribution of oncogenic
HPV (indicated by HPV genotype-16 and/or 18) among
cases and controls. It shows that, in controls, prevalence
of HPV 16 and 18 is almost constant (approx. 9%)
across different age groups. But, in cases, prevalence of
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valence decreases. Prevalence of HPV is higher among
cases in each age group compared to controls.
Figure 2 describes distribution of oncogenic HPV in
relation to duration of active sexual life. It is evident
that among controls prevalence of oncogenic HPV
shows a slightly decreasing trend with increase in dura-
tion of sexual life whereas among cases it shows a rising
trend. Secondly, prevalenceo fo n c o g e n i cH P Vi sm u c h
higher in cases compared to controls for any particular
duration of active sexual life.
Figure 3 shows age-wise distribution of HPV among
cases and controls with duration of sexual life of 5 year
or less. Interestingly, in this group HPV prevalence
showed a steadily increasing trend with age among both
HIV positive and negative females. Whereas, when
Table 1 Socio-demographic variables of study population according to HIV sero-status
Variable HIV positive
women
(n = 93)
HIV negative
women
(n = 1106)
P value Comments
Mean age
29 yrs 30 yrs P-value > .001 There is not convincing evidence that HIV positive and negative samples
differ with respect to mean age
Religion
Hindu 82% 65% P-value > .001 There is not convincing evidence that HIV positive and negative samples
differ with respect to religion
Muslim 18% 31%
Christian 0% 4%
Education
Illiterate 52% 25% P-value < .001 HIV positive and negative samples differ with respect to literacy status
Primary 25% 64%
Secondary 13% 6%
Higher Secondary &
College
11% 5%
Mean age of marriage
18 years 16 years P-value < .001 HIV positive and negative samples differ with respect to mean age of
marriage
Mean duration of sexual life
10 years 13 years P-value < .001 HIV positive and negative samples differ with respect to mean duration of
sexual life
Life time sexual partners
1 96% 99% P-value could not be calculated because one of the expected counts was less than 5
24 % 1 %
Parity
0 6% 6% P-value > .001 There is not convincing evidence that HIV positive and negative samples
differ with respect to parity
1-2 51% 56%
> 2 43% 38%

Figure 1 Distribution of HPV-16 & 18 among women with and
without HIV infection by age.

Figure 2 D i s t r i b u t i o no fH P V - 1 6&1 8i nr e l a t i o nt os e x u a l
duration in HIV+ve & HIV-ve subjects.
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prevalence of HPV shows a decreasing trend with age
till 30 years for both cases and controls. Beyond
30 years, the prevalence shows an almost parallel trend
among controls but, it steadily increases among cases
till 40 years beyond which it again declines.
On univariate analysis, the significant predictors of
HPV infection were HIV, age, and duration of sexual
life. Though other demographic predictors such as edu-
cation level, religion and socio-economic status have
been found to be confounding factors in other published
study, these factors did not seem to be significant con-
founders in our study. Next, both bivariable and multi-
variable logistic regression analysis were conducted to
further analyze data. In bi-variable logistic regression
Wald chi-square test statistic and p value was used. In
bi-variable models HIV was a significant predictor of
HPV (OR = 4.8, CI 2.9 - 7.8, p < 0.05). Neither age
(OR = 0.9, CI 0.9 - 1.0, p > 0.5) nor duration of sexual
life (OR = 0.9, CI 0.9 - 1.0, p > 0.05) were found to be
statistically significant as predictors of HPV. Next, we
conducted multivariable logistic regression to find out if
multicollinearity or synergism existed between the three
predictors (HIV, age, and duration of sexual life). Chi
square (likelihood ratio) and p value were used as test
statistics. After adjusting for age and duration of sexual
life, the OR for HIV was 4.9 (CI 2.9 - 8.0, p < 0.05) i.e.
the odds of having HPV infection were 4.9 times higher
among HIV sero-positive women than HIV sero-
negative women. Age and duration of sexual life were
not statistically significant predictors of HPV after
adjusting for HIV status and duration of sexual life, and
HIV status and age, respectively (Age: OR = 0.9,
CI 0.9 - 1.0, p > 0.05; Duration of sexual life: OR = 1.01,
CI 0.9 to 1.1, p > 0.05).
Distribution of the oncogenic HPV in HIV infected
subjects is shown in Figure 5. It is evident that onco-
genic genotype-18 was the predominant pathogen (19%)
followed by that of type-16 (16%) in HIV infected study
subjects. Strikingly, prevalence of HPV 18 among the
controls was found to be very low (0.9%; n = 10).
Among other genotypes, HPV 52, 58 and 39 were
observed in a sizable portion of cases. This is a matter
of concern.
About 17% (n = 15) of the cases were infected by mul-
tiple oncogenic strains of HPV of which 8 were infected
with dual genotypes, 6 were infected with triple geno-
types and only 1 was infected with 4 genotypes. HPV 16
and/or 18 were present in 13 out of 15 multiple geno-
type infected cases.
Discussion
In this study it was observed that the prevalence of HPV
16 and or18 among HIV negative female population to
be 9.1% which is comparable to findings from various
other studies conducted in India. [9] The study demon-
strates significantly higher prevalence of oncogenic HPV
(all genotypes) and HPV 16/18 among HIV positive
cases compared to HIV negative controls. Two earlier
studies from western and southern India and studies
conducted in other parts of the world have also docu-
mented similar findings. [12-16]. This study has also
documented that HIV positive females are at increased
risk of getting infected with oncogenic HPV than the
HIV negative females irrespective of age and sexual life
duration and risk becomes higher when age more than
30 year and sexual exposure duration more than 5 year.

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Figure 3 Age-wise distribution of HPV-16 & 18, when duration
of sexual act < = 5 yr.
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Figure 4 Age-wise distribution of oncogenic HPV-16 & 18
when duration of sexual act > 5 yr.

Figure 5 Distribution of oncogenic HPV genotypes among HIV
infected subjects tested by Roche kits (n = 93).
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seen in more advanced HIV infected cases.
Generally HPV prevalence in women shows a peak at
younger ages and then declines over the age of 30 years
[7,8]. Even in studies among sex workers, a population
which is highly exposed to HPV, Kjaer et al. and Sarkar
et al observed a considerably decreasing trend in HPV
prevalence with age in spite of continuous high levels of
sexual activity. [17,18] This is probably due to develop-
ment of acquired immunity to HPV infection following
repeated exposure. But, in this study, it was found that
the prevalence of HPV 16/18 to be almost constant
across different age groups among the controls. Similar
findings were noted in other studies on HPV epidemiol-
ogy in the Indian Subcontinent where oncogenic HPV
prevalence did not vary significantly across age groups
in India. [19-23] There was no clear peak of HPV preva-
lence in young women. However it should be noted that
in these studies and also in the current study, subjects
included were primarily married women. This was
because in India genital tract sampling of an unmarried
woman is associated with cultural and social taboo.
Socio-cultural practices specifically related to Indian
married women might have played a role in the lack of
a peak in HPV prevalence among younger age groups.
In the present study most of the cases reported to have
monogamous relationship (96%, n = 89). Number of life
time partners, sexual behavioral patterns, number of
pregnancies, genital hygiene, presence of other STDs,
socio-economic conditions, literacy status, underrepre-
sentation of teenagers in the study samples etc. might
have influenced the low clearance of incident HPV
infections and may be responsible for the constant,
steady prevalence of HPV in different age groups in
India. On the other hand, frequent re- infection/reacti-
vation due to multiple sex-partners, increased frequency
of sex etc. might have helped in the development of
immunity against HPV among sex workers in the study
by Sarkar et al. [18] which included young unmarried
women. An in-depth cohort study from this region is
required to understand this.
In HIV positive females, prevalence of HPV 16 and/
or18 showed a rising trend till 40 years after which it
declined. Since this was a cross-sectional study it was
impossible to determine whether HPV infection fol-
lowed HIV or otherwise. But earlier studies have shown
that presence of HIV infection facilitates the develop-
ment and persistence of HPV infection. This may be
because HIV infection lowers body immunity. So, co-
infection with HIV can be a probable explanation for
acquisition of new HPV infections later in life, delayed
clearance of HPV with age and reactivation of latent
infections acquired earlier in life due to a gradual loss of
immunity. The decline of HPV prevalence beyond
40 years may be influenced by less number of subjects
caused by death due to AIDS, increased immunity
following receiving ART etc.
Duration of sexual activity had opposite influence on
HPV 16 and/or18 prevalence among HIV positive and
negative subjects. HPV showed rising trend with
increase in duration of sexual activity in HIV positive
females whereas it showed a decline with increase in
duration of sexual activity among HIV negative females.
But, when adjusted for both age and duration, HPV pre-
valence showed a steady rise till 30 years of age in cases
and controls when duration of active sexual life was less
than equal to 5 years. However, when duration was
more than 5 years, HPV declined with age till 30 years
in both HIV positive and negative females. This may
probably be due to development of immunity against
HPV with higher duration of sexual life. So, duration of
sexual life is perhaps a greater determinant of develop-
ment of immunity and clearance of HPV than age alone
till 30 years even in the presence of HIV. After 30 years,
even with higher duration of sexual life HPV showed a
constant prevalence with increase in age in HIV negative
subjects whereas in the HIV positive group HPV
increased with age till 40 years beyond which it again
declined. In this study we were unable to compare these
trends with those in population above 30 years of age
but duration of sexual life less than equal to 5 years
since none of the subjects belonged to this group. How-
ever, in multivariate analysis neither age nor duration of
sexual life were found to be significant predictors of
HPV infection. HIV co-infection was the only significant
predictor of HPV infection and HIV positive women
were almost five times more likely to be infected by
oncogenic HPV compared to HIV negative women.
Previous studies in India have reported circulating
strains of oncogenic genotypes other than HPV 16 and/
or18 in the general population [9]. But adequate data is
not available regarding oncogenic strains of HPV other
t h a nH P V 1 6a n d / o r 1 8i nH I Vi n f e c t e dI n d i a nw o m e n
especially from Eastern India. Due to resource con-
straints we were only able to perform a PCR assay of
cervical specimens obtained from HIV positive subjects.
Our findings document the presence of almost all onco-
genic genotypes of HPV in HIV positive females.
Among controls HPV 18 showed a much lower preva-
lence than HPV 16 (0.9% vs. 9%). Similar findings were
noted in other studies from different parts of India. [9]
However, among HIV +ve subjects, HPV 18 showed the
highest prevalence followed by HPV 16. This predomi-
nance of HPV 18 among HIV positive women in a set-
ting where HPV 16 is the most prevalent genotype
among HIV negative women requires further explora-
tion. Demographic differences in the study population
in terms of education, age of marriage and duration of
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different genotypes. Unfortunately cytological tests were
not a part of the study due to lack of resources. There-
fore, further research needs to be done to see if the pre-
dominance of HPV 18 in HIV positive subjects was due
to an increased number of cases of adeno-squamous
lesions in this population. Another possible cause may
be higher transmission potential of HPV-18 among HIV
+ve subjects. Strikingly, about 53% (23/43) of cases with
oncogenic HPV were infected with genotypes other than
16 and/or18 either as single/multiple infections. In a
review article by McKenzie et al. HIV infected women
in different geographic regions appeared to be infected
with less prevalent types of HR-HPV as compared to
the general population. [24] High-risk HPV types were
isolated from 97% of cervical cancer cases, and HPV-16/
18 were found in 80% of cervical neoplasia in India
[9,19-23]. This shows that oncogenic HPV other than
HPV 16/18 plays a substantial role in the development
of cervical cancer especially in HIV infected women.
Conclusion
With the advent of ART, HIV positive women tend to
live longer. Since cervical cancer generally develops in
older age groups, therefore in the era of ART, there is
an increased chance of cervical cancer cases among HIV
positive women because of longer survival period. Infor-
mation on interaction between HIV and HPV is there-
fore important to understand individual influence of
each virus against the other. The currently available
HPV vaccines offer protection only against HPV 16 and
18 and some cross-protection to few associated geno-
types. Moreover, there is lack of evidence of immuno-
genicity in HIV infected individuals following receiving
HPV 16/18 vaccines. These vaccines are therefore less
likely to offer protection against cervical cancer in HIV
positive women who harbor a high percentage of other
oncogenic HPV genotypes. Therefore in HIV positive
women early detection of oncogenic HPV & cervical
cytological abnormality followed by an appropriate treat-
ment is possibly the best approach at present.
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